Press Releases

Date	Title	PDF Version
Oct 23, 2017	FDA Approves Soliris® (Eculizumab) for the Treatment of Patients with Generalized Myasthenia Gravis (gMG)
Oct 10, 2017	Alexion to Report Third Quarter 2017 Results on Thursday, October 26, 2017
Sep 14, 2017	Alexion Adds Paul A. Friedman, M.D. to Its Board of Directors
Sep 13, 2017	Interim Analysis from Phase 3 Open-Label Extension Study Shows Sustained Benefits of Soliris® (Eculizumab) Treatment for Patients with Refractory Generalized Myasthenia Gravis
Sep 12, 2017	Alexion Announces Restructuring to Advance Corporate Strategy
Sep 11, 2017	Alexion to Host Call to Discuss Restructuring to Advance Corporate Strategy at 8:30 a.m. on September 12, 2017
Sep 05, 2017	Alexion to Present at Upcoming Investor Conferences
Aug 21, 2017	European Commission Grants New Indication for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG)
Aug 15, 2017	Alexion Receives Three New U.S. Patents for Soliris® (eculizumab), Extending Patent Protection Into 2027
Aug 10, 2017	Alexion and Sema4 Partner in Rare Disease Diagnostics and Systems Biology

Search